Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat

Summary

Electrical stimulation of the rat carotid artery causes a deep medial injury and the formation of a platelet-rich thrombus.

Occlusive thrombosis at sites of vessel wall injury was significantly reduced after the oral administration of clopidogrel, a potent analogue of ticlopidine, which showed dose-dependent inhibition of the thrombus formation (ED₅₀ = 1.0 ±0.2 mg/kg, p.o.). Accumulation of thrombotic material was also considerably reduced after the i. v. administration of SR 27417, a highly potent and selective platelet activating factor receptor antagonist (ED₅₀ = μg/kg, i.v.), nafagrel, a thromboxane A₂ synthetase inhibitor (ED₅₀ = 1.3 mg/kg, i.v.) and hirudin (ED₅₀ = 140 μg/ kg, i.v.). A high dose (20 mg/kg, i.v.) of the anti-adhesive tetrapeptide Arg-Gly-Asp-Ser (RGDS) showed only a slight effect on thrombus formation whereas aspirin was ineffective.

These results confirm that ADP and thromboxane A₂ play key roles in the initiation and progression of arterial thrombus formation and suggest that platelet activating factor may also modulate thrombosis in this experimental model.

• References

• 1 Hass WK, Easton D, Adams HP. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507
• 2 Meier B. Prevention of restenosis after coronary angioplasty: a pharmacological approach. Eur Heart J 1989; 10 (suppl G): 64-68
• 3 Webster MWJ, Chesebro JH, Fuster V. Platelet inhibitor therapy. Agents and clinical implications. Hematol Oncol Clin N America 1990; 4: 265-289
• 4 Cadroy Y, Harker LA. Platelets, thrombosis and antithrombotic therapies. In: Cardiovascular Pharmacology. Antonacio M. (ed) 03. edition New York: Raven Press; 1990: 515-539
• 5 Weber MAJ, Hasford J, Taillens C. Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion. Am J Cardiol 1990; 66: 1461-1468
• 6 Lekstrom JA, Bell WR. Aspirin in the prevention of thrombosis. Medicine 1991; 70: 161-177
• 7 Hladovec I. Experimental arterial thrombosis in rats with continuous registration. Thromb Diathes Haemorrh 1971; 26: 407-410
• 8 Ubatuba FB. An animal model for the study of arterial thrombosis. Braz J Med Biol Res 1989; 22: 993-1000
• 9 Maffrand JP, Bernat A, Delebassée D, Defreyn G, Cazenave JP, Gordon JL. ADP plays a key role in thrombogenesis in rats. Thromb Haemostas 1988; 59: 225-230
• 10 Herbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation following arterial injury. Arteriosclerosis and Thrombosis 1993; 13: 1171-1179
• 11 Simpson PJ, Smith CB, Rosenthal G. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury. J Pharmacol Exp Ther 1986; 238: 497-501
• 12 Randall MJ, Wilding RI. Acute arterial thrombosis in rabbits: Reduced platelet accumulation after treatment with dazoxiben hydrochloride. Br J Clin Pharmacol 1983; 15: 49S-55S
• 13 De Clerk F, Van Corp L, Beetens J. Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive injury in the rat. Blood Coag Fibrinol 1990; 1: 247-258
• 14 Kunitada S, Irie K, Tamura K, Ashida S, Akashi A. DP 1904, a novel TXA₂ synthetase inhibitor. Jap J Pharm 1986; 40: 95P
• 15 Bourgain RH, Maes L, Braquet P, Andries R, Touqui R, Braquet M. The effect of l-0-alkyl-2-acetyl-SN-glycero-3-phosphacholine (PAF-acether) on the arterial wall. Prostaglandins 1985; 30: 185-197
• 16 Herbert JM, Bernat A, Valette G, Gigo V, Lale A, Laplace MC, Lespy L, Savi P, Maffrand JP, Le Fur G. Biochemical and pharmacological activities of SR 27417, a highly potent, long acting platelet activating factor receptor antagonist. J Pharmacol Exp Ther 1991; 259: 44-51
• 17 Golino P, Buja LM, Ashton JM, Kulkarni P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists in intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation 1988; 78: 701-711
• 18 Aiken JW, Shebuski R, Miller V, Gorman RR. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther 1981; 219: 299-308
• 19 Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR. Effect of OKY-1581, a thromboxane synthetase inhibitor on coronary thrombosis in the conscious dog. Eur J Pharmacol 1984; 105: 285-291
• 20 FitzGerald GA, Reily IA, Pedersen AK. The biochemical pharmacology of thromboxane synthetase inhibition in man. Circulation 1985; 72: 1194-1201
• 21 Plotkine M, Massad L, Allix M. A new arterial thrombosis model to study antithrombotic agents: efficacy of naftidrofuryl. Clin Hemorheol 1989; 9: 339-349
• 22 Massad L, Plotkine M, Capdeville C, Boulu RG. Electrically induced arterial thrombosis model in the conscious rat. Thromb Res 1987; 48: 1-10
• 23 Reyers I, Mussoni L, Donati MB, De Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-674
• 24 Reyers I, Hennissen A, Donati MB, Hornstra G, De Gaetano G. Aspirin and the prevention of experimental arterial thrombosis: difficulty in establishing unequivocal effectiveness. Thromb Haemostas 1985; 54: 619-621
• 25 Ashida S, Sakuma K, Abiko Y. Antithrombotic effects of ticlopidine, acetylsalicylic acid and dipyridamole in vascular shunt model in rats. Thromb Res 1980; 17: 663-671
• 26 Killackey JJF, Killackey BA, Philip RB. The effects of high doses of aspirin and related benzoic acid derivatives on arterial thrombosis in male rats. Haemostasis 1984; 14: 354-360
• 27 Gresele P, Vanhoutte E, Amout J, Deckmyn H, Vermylen J. Thromboxane synthetase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?. Thromb Haemostas 1984; 52: 364
• 28 FitzGerald DJ, Fragetta J, Fenelon LC, FitzGerald GA. Thromboxane synthetase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis. Adv Prostagland Thrombox Leukotriene Res 1987; 17: 496-498
• 29 Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts II LJ. Clinical implications of prostaglandin and thromboxane A₂ formation. New Engl J Med 1988; 319: 689-698
• 30 Vandeplassche L, Hermans C, Van de Water A, Xhonneux R, De Clerck F. Differential effects of TXA₂ synthetase inhibition, singly or combined with TXA₂/βPGH₂ receptor antagonism (R 68070) on thrombosis over endothelial cell damage or deep intimal injury in canine coronary arteries. Thromb Haemostas 1989; 62: 170-182
• 31 Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986; 44: 517-525
• 32 Cadroy Y, Houghten RA, Hanson ST. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. J Clin Invest 1989; 84: 939-944
• 33 Coller BS, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein Ilb-IIIa receptor in an experimental model. Blood 1986; 68: 783-786
• 34 Harfenist EL, Packham MA, Mustard JE. Effect of the cell adhesion – peptide, Arg-Gly-Asp-Ser, on the responses of washed platelets from humans, rabbits and rats. Blood 1988; 71: 132-136
• 35 Mann KG, Tracy PG, Krishnaswamy S, Jenny RJ, Odegaard BH, Nesheim ME. Platelets and coagulation. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds) Leuven: University Press; 1987: 505-524
• 36 Walsh PN, Griffin JH. Contribution of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 1981; 57: 106-118
• 37 Talbot MD, Ambler J, Butler KD. Recombinant desulphatohirudin (CGP 39393). Anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 1990; 64: 464-480
• 38 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-378
• 39 Butler KD, Ambler J, Dolan S, Giddings J, Talbot MD, Wallis RB. A non-occlusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function, or thrombin activity. Blood Coag Fibrinol 1992; 3: 155-165
• 40 Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989; 15: 269-282
• 41 Terashita ZI, Imura Y, Nishikawa K. Inhibition by CV-3988 of the binding of [³H]-platelet activating factor (PAF) to the platelets. Biochem Pharmacol 1985; 34: 1491-1495
• 42 Weichert W, Breddin HK. A PAF-acether antagonist (N 48740 RP) and laser-induced thrombi in rat mesenteric vessels. Haemostasis 1989; 19: 229-234